Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:08:04 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:CAPR - CAPRICOR THERAPEUTICS INC - https://www.capricor.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CAPR - Q0.16.87·7.005.06.88-0.28-3.92,098.314,1969,1537.16  7.27  6.8823.40  3.5219:45:11Jul 1115 min RT 2¢

Recent Trades - Last 10 of 9153
Time ETExPriceChangeVolume
19:45:11Q6.9597-0.200329
19:40:29Q6.95-0.211
19:34:20Q6.96-0.20500
19:26:14Q6.96-0.2041
19:25:10Q6.9599-0.2001400
19:23:47Q6.9597-0.200314
19:15:03Q6.96-0.2010
19:14:16Q6.96-0.204
19:14:13Q6.96-0.2060
19:00:35Q6.97-0.19150

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-11 06:30U:CAPRNews ReleaseCapricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
2025-06-24 09:00U:CAPRNews ReleaseCapricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
2025-06-20 09:25U:CAPRNews ReleaseCapricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
2025-06-17 09:00U:CAPRNews ReleaseCapricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
2025-06-11 09:25U:CAPRNews ReleaseCapricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
2025-05-13 16:05U:CAPRNews ReleaseCapricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-13 09:00U:CAPRNews ReleaseCapricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
2025-05-06 09:15U:CAPRNews ReleaseCapricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
2025-05-05 08:00U:CAPRNews ReleaseCapricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
2025-04-01 09:00U:CAPRNews ReleaseCapricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day
2025-03-19 16:05U:CAPRNews ReleaseCapricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2025-03-17 09:25U:CAPRNews ReleaseCapricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
2025-03-11 09:00U:CAPRNews ReleaseCapricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
2025-03-10 09:13U:CAPRNews ReleaseFDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
2025-03-07 09:25U:CAPRNews ReleaseCapricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025
2025-03-04 07:00U:CAPRNews ReleaseCapricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
2025-02-10 09:00U:CAPRNews ReleaseCapricor Therapeutics to Participate in Upcoming Investor Conferences
2025-01-02 09:15U:CAPRNews ReleaseCapricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
2024-12-02 16:15U:CAPRNews ReleaseCapricor Therapeutics to Present at Upcoming Investor Conferences
2024-11-20 09:00U:CAPRNews ReleaseCapricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency